Immune mechanisms in hypertension.
Low grade inflammation may have a key role in the pathogenesis of hypertension and cardiovascular disease. Several studies showed that both innate and adaptive immune systems may be involved, being T cells the most important players. Particularly, the balance between Th1 effector lymphocytes and Treg lymphocytes may be crucial for blood pressure elevation and related organ damage development. In the presence of a mild elevation of blood pressure, neo-antigens are produced. Activated Th1 cells may then contribute to the persistent elevation of blood pressure by affecting vasculature, kidney and perivascular fat. On the other hand, Tregs represent a lymphocyte subpopulation with an anti-inflammatory role, being their activity crucial for the maintenance of cardiovascular homeostasis. Indeed, Tregs were demonstrated to be able to protect from blood pressure elevation and from the development of organ damage, including micro and macrovascular alterations, in different animal models of genetic or experimental hypertension. In the vasculature, inflammation leads to vascular remodeling through cytokine activity, smooth muscle cell proliferation and oxidative stress. It is also known that a consistent part of ischemia-reperfusion-induced acute kidney injury is mediated by inflammatory infiltration and that Treg cell infusion have a protective role. Also the central nervous system has an important role in the maintenance of cardiovascular homeostasis. In conclusion, hypertension development involves chronic inflammatory process. Knowledge of cellular and molecular players in the progression of hypertension has dramatically improved in the last decade, by assessing the central role of innate and adaptive immunity cells and proinflammatory cytokines driving the development of target organ damage. The new concept of role of immunity, especially implicating T lymphocytes, will eventually allow discovery of new therapeutic targets that may improve outcomes in hypertension and cardiovascular or renal disease in humans and uncover an entirely novel approach in the treatment of hypertension and vascular disease.
Clinica Medica, Department of Clinical and Experimental Sciences, c/o 2a Medicina Spedali Civili di Brescia, University of Brescia, Piazza Spedali Civili 1, 25100, Brescia, Italy.
Carolina
C
De Ciuceis
Claudia
C
Rossini
Elisa
E
La Boria
Enzo
E
Porteri
Beatrice
B
Petroboni
Alice
A
Gavazzi
Annamaria
A
Sarkar
Enrico Agabiti
EA
Rosei
Damiano
D
Rizzoni
D056704:Adaptive Immunity / Q000276:immunology; D000818:Animals; D016207:Cytokines / Q000276:immunology; D018450:Disease Progression; D006801:Humans; D006973:Hypertension / Q000276:immunology*; D006978:Hypertension, Renovascular / Q000276:immunology; D007113:Immunity, Innate / Q000276:immunology; D007249:Inflammation / Q000276:immunology; D016176:T-Lymphocyte Subsets / Q000276:immunology
D016207:Cytokines